Skip to main content

J&J's SEC Filing Indicates $3.9B Reserved For Talc Lawsuits

J&J's SEC Filing Indicates $3.9B Reserved For Talc Lawsuits

J&J's SEC Filing Indicates $3.9B Reserved For Talc Lawsuits

Introduction

An Annual Report Pursuant to Section 13 of the Securities Exchange Act of 1934, filed by the talcum powder giant Johnson & Johnson (J&J) indicated that the manufacturer has set aside $3.9 billion in litigation expenses in 2020, which is primarily associated with talc-related reserves and certain settlements.

The Form 10-K document filed on February 22 with the U.S. Securities and Exchange Commission (SEC) also indicated the company’s position in other ongoing litigations, which included hip replacement devices, Xarelto, Invokana, Risperdal, pelvic mesh products, and Elmiron.

In its filing, the company noted that it is facing more than 25,000 Baby Powder and Shower-to-Shower lawsuits by former users, claiming asbestos-laced talc in the product resulted in their cancers.

Last month, the Kentucky Court of Appeals reversed a verdict that favored the company over a lawsuit claiming its baby powder for a deceased woman's cancer. The appellate court reversed the verdict after finding that the trial court’s decision over allowing the defendant to elicit “irrelevant personal and family use testimony from its witness” prejudiced the plaintiff. The court also remanded the case for a new trial against the company.

A $2.12 billion verdict, which was awarded to women who alleged the company's products for their ovarian cancer is also being appealed by the company in the U.S. Supreme Court.

Last year the company stopped selling its talcum-based products in the U.S. and Canada, stating a decline in consumer demand and misinformation about the safety of the products.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.